Oxford Biodynamics PLC (OBD) - Total Liabilities

Latest as of September 2025: GBX6.97 Million GBX ≈ $848.05 USD

Based on the latest financial reports, Oxford Biodynamics PLC (OBD) has total liabilities worth GBX6.97 Million GBX (≈ $848.05 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore OBD shareholders equity momentum to track the company's year-over-year net asset growth rate.

Oxford Biodynamics PLC - Total Liabilities Trend (2013–2025)

This chart illustrates how Oxford Biodynamics PLC's total liabilities have evolved over time, based on quarterly financial data. See Oxford Biodynamics PLC free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Oxford Biodynamics PLC Competitors by Total Liabilities

The table below lists competitors of Oxford Biodynamics PLC ranked by their total liabilities.

Company Country Total Liabilities
Amur Minerals Corporation
LSE:CRTX
UK GBX583.34K
Tiger Royalties and investments Plc
LSE:TIR
UK GBX91.36K
Serinus Energy
LSE:SENX
UK GBX50.04 Million
Fadel Partners Inc
LSE:FADL
UK GBX6.56 Million
Harmony Energy Income Trust PLC
LSE:HEIT
UK GBX373.69K
Bisichi Mining PLC
LSE:BISI
UK GBX22.12 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Oxford Biodynamics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OBD market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.88 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 6.25 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.86 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oxford Biodynamics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oxford Biodynamics PLC (2013–2025)

The table below shows the annual total liabilities of Oxford Biodynamics PLC from 2013 to 2025.

Year Total Liabilities Change
2025-09-30 GBX6.97 Million
≈ $848.05
-10.06%
2024-09-30 GBX7.75 Million
≈ $942.95
-23.05%
2023-09-30 GBX10.07 Million
≈ $1.23K
+15.03%
2022-09-30 GBX8.76 Million
≈ $1.07K
+0.81%
2021-09-30 GBX8.69 Million
≈ $1.06K
+390.18%
2020-09-30 GBX1.77 Million
≈ $215.60
+47.91%
2019-09-30 GBX1.20 Million
≈ $145.76
+34.30%
2018-09-30 GBX892.00K
≈ $108.53
-17.71%
2017-09-30 GBX1.08 Million
≈ $131.89
-15.11%
2016-09-30 GBX1.28 Million
≈ $155.37
+82.95%
2015-09-30 GBX698.00K
≈ $84.93
-26.37%
2014-09-30 GBX948.00K
≈ $115.34
+43.64%
2013-09-30 GBX660.00K
≈ $80.30
--

About Oxford Biodynamics PLC

LSE:OBD UK Diagnostics & Research
Market Cap
$57.43K
GBX472.00 Million GBX
Market Cap Rank
#31468 Global
#1183 in UK
Share Price
GBX0.11
Change (1 day)
-4.35%
52-Week Range
GBX0.09 - GBX0.59
All Time High
GBX274.50
About

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more